Eli Lilly is discontinuing specific insulin product presentations in selected countries. The European Medicines Agency (EMA) announced the move on March 23, 2026. Initial reports omit specific versions and affected regions.
This adjustment follows a strategic focus on GLP-1 treatments. Mounjaro and Zepbound drive the company's market valuation. These blockbuster drugs target diabetes and weight loss.